PALB2 and prostate cancer: Consequently, many HR deficient cases are identified by sequencing BRCA1/2 or PALB2, and this approach has led to initial approval of PARP inhibitors in multiple tumor types including breast, ovarian, pancreatic, and prostate cancer.